- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen
- Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré
- Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
- Evaxion Announces Business Update and Full Year 2023 Financial Results
- Evaxion organise la journée de la recherche et développement et dévoile le vaste potentiel de sa plateforme AI-Immunology™
- Evaxion veranstaltet F&E-Tag und stellt das breite Potenzial seiner AI-Immunology™-Plattform vor
- Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
- Evaxion veranstaltet am 19. März 2024 F&E-Tag zur Vorstellung seiner neuesten technologischen Innovationen
- Evaxion organisera une journée R&D le 19 mars 2024 lors de laquelle elle mettra en avant ses dernières innovations technologiques
More ▼
Key statistics
As of last trade, Evaxion Biotech A/S (EVAX:NAQ) traded at 4.13, 46.23% above the 52 week low of 2.82 set on Mar 07, 2024.
52-week range
Open | 4.18 |
---|---|
High | 4.18 |
Low | 4.05 |
Bid | 3.82 |
Offer | 4.17 |
Previous close | 4.13 |
Average volume | 26.90k |
---|---|
Shares outstanding | 521.51k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 21.54m USD |
EPS (TTM) | -81.29 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼